



is causally linked to mutations in nuclear
genes encoding structural or regulatory
proteins of the sarcomere1 and, less fre-
quently, to mutations in mitochondrial (mt)
DNA genes2. To date, many mtDNA muta-
tions associated with the mitochondrial
myopathy, encephalopathy, lactic acidosis,
and stroke-like episode (MELAS) syn-
drome have been identified. They include: 
• ribosomal RNA/transfer (t) RNA transi-
tions at 5833, 16424, 30935, 32436-10,
325211, 325612,13, 327113, 329114 and
431715 bp;
• coding region transitions at 330816-18,
995719, 1108420,21, 1214722, 1351323,24,
1351425 and 1445326 bp;
• a 4 bp deletion extending from the 14787
to 14790 nucleotide positions27.
Two of the former tRNA defects, the
G3243A6-10 in the tRNALEU (UUR) and the
A4317G15 in the tRNAIle, have been causal-
ly linked to MELAS with HCM. 
Due to the peculiar features of mtDNA,
a single point mutation in a mt-tRNA may
cause severe organ/tissue disease. In fact,
the protein synthesis apparatus of mito-
chondria works under extremely economic
conditions since mtDNA codes for both
rRNA subunits and for 22 tRNAs. This im-
plies that even a single point mutation in a
key position of a mtDNA-coded RNA may
severely impair all the mitochondrial pro-
tein synthetic systems reflecting its nega-
tive effect on 4 out of 5 mitochondrial com-
plexes (complexes I, III, IV and V) that are
partly made up of polypeptides synthesized
in the mitochondria. Furthermore, mtDNA-
related diseases are complicated by the ma-
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Background. Pathological mutations of mitochondrial (mt) DNA may cause specific diseases such
as cardiomyopathies or hearing loss, or syndromes such as mitochondrial myopathy, encephalopathy,
lactic acidosis, and stroke-like episode (MELAS) syndrome. We describe a novel mtDNA mutation in a
patient with severe hypertrophic cardiomyopathy associated with MELAS. The familial phenotype
included 1) hypertrophic cardiomyopathy and MELAS, 2) clinically mild cardiac hypertrophy, and
3) deafness.
Methods. The proband and her first degree relatives underwent echo and electrocardiograms, and
biochemical tests. Magnetic resonance imaging of the brain was performed in the proband. mtDNA
was fully analyzed by sequencing. DNA purification, polymerase chain reaction and direct automat-
ed sequencing were performed following standard procedures. Heteroplasmy of the novel mutation
was quantified by densitometric analysis.
Results. A novel G1644A transition affecting the tRNAVal was identified in the proband and ma-
ternal relatives. The mutation has been interpreted as pathological because the G at the 1644 position
is a highly conserved base, is heteroplasmic with higher levels of mutant DNA in the proband than in
the relatives, is located in the unique tRNAVal, is very close to a mutation described as causative of
MELAS, and finally has not been found in 100 healthy controls.
Conclusions. Although it is rare for patients with MELAS to be referred to cardiological evalua-
tion because of coexisting cardiomyopathy, cardiologists should be aware of this association as well as
of the non cardiac signs that may address the diagnosis to mtDNA defect-related disease in families
with a variable phenotype.
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their pleiotropic effect, incomplete penetrance, variable
expression and heteroplasmy, i.e. the coexistence in the
same tissue/cells of both mutated and wild type mtDNA
at variable percentages. Thus, an identical mutation
may cause different pathological phenotypes in differ-
ent subjects within the same family, ranging from very
mild clinical phenotypes to fully expressed diseases.
Stochastic distribution to daughter cells of mitochon-
dria containing normal and/or mutated mtDNA mole-
cules plays a fundamental role in at least some unique
pathological mtDNA features making it difficult: i) to
foresee the percentage of affected molecules transmit-
ted from cell to cell in a given tissue, ii) to infer, on the
basis of the quantity found in other tissues, the amount
of mutated mtDNA molecules of a tissue, and finally,
iii) to establish reliable rules for genetic counseling.
In the present study, we report a novel pathological
mtDNA mutation in the tRNAVal in a family in which
the proband was diagnosed with HCM and MELAS,
her mother with mild hypertrophy and both mother and
grandmother with sensorineural deafness.
Methods
Family members and controls. The proband and her
relatives were clinically investigated at the Cardiology
Division of the University of Modena (Italy). They un-
derwent interview, physical evaluation, electrocardiog-
raphy, echocardiography and biochemical tests includ-
ing serum creatine phosphokinase. Magnetic resonance
imaging of the brain was performed on the proband.
Controls for mtDNA study consisted of 100 healthy
Italian Caucasoid subjects.
Amplification and nucleotide sequence determina-
tion. DNA was purified by a standard phenol-chloroform
method. Polymerase chain reaction amplification was
performed by using 200 ng of total DNA in accordance
with standard protocols. The entire mtDNA molecule was
amplified by polymerase chain reaction and sequenced as
previously described28. For the region including the
tRNAVal gene, forward 5’-TTAACTAAAACCCCTACG-
CA-3’ and reverse 5’-CGCCTATACTTTATTTGGGT-3’
primers were used. Direct automated sequencing was car-
ried out on amplified fragments in a 3100 ABI PRISM
genetic analyzer (Applied Biosystem, Foster City, CA,
USA). The mutated amplicons, obtained with the mis-
match primer 5’-GCGGTCAAGTTAAGTTGAGAT-3’
(nucleotide position 1647 underlined), were digested
with the MboI restriction enzyme.
Analysis of the nuclear genes causally linked to
HCM was not performed on the basis of clinical indi-
cations of a mtDNA-related disease in the proband.
Heteroplasmy quantification. The heteroplasmy of
the G1644A mutation was quantified by densitometric
analysis with a Gel Doc 2000 BIO-RAD instrument
(Hercules, CA, USA).
Results
A novel mtDNA mutation was identified in a fami-
ly (Fig. 1A) in which the phenotype ranged from mild
left ventricular hypertrophy (II-2), cystic kidney dis-
ease (II-3, II-4, II-5), deafness (I-2, II-2), the absence of
any clinical phenotype at the time of clinical evaluation
(III-1) and severe HCM with MELAS (III-2).
Clinical data. A 33-year-old female (Fig. 1A, III-2)
was referred for cardiological evaluation because of re-
cent-onset dyspnea, peripheral edema and weight loss.
At entry, she was diagnosed with HCM and pericardial
effusion. Electrocardiography showed left cardiac hy-
pertrophy and ventricular pre-excitation with a Kent
branch. Echocardiography showed a left atrium at the
upper limits of normal and left ventricular hypertrophy
with a mean diastolic thickness of 3.6 cm and without
a significant left ventricular outflow tract obstruction
neither in basal conditions nor after provocative ma-
neuvers (Valsalva and sublingual nitrate). No systolic
anterior movement of the mitral valve apparatus was
therefore detectable. The right ventricular wall was al-
so hypertrophic. The left ventricular ejection fraction
was decreased (35%), and there was a diastolic pattern
of abnormal relaxation. All the hypertrophied my-
ocardium showed a typical sparkling echo-texture
which is a well-known ultrasonic feature of myocardial
fiber disarray. Biochemical analysis documented in-
creased levels of serum creatinine (3.6 mg/dl), glucose
(146 mg/dl) and serum creatine phosphokinase (380
U/l). Other clinical features included mental retarda-
tion, muscular ataxia, sensorineural hearing loss and
cystic renal disease. Brain magnetic resonance imaging
showed widespread cerebral atrophy with secondary
enlargement of the subarachnoid cistern. The patient
was diagnosed with HCM associated with MELAS
syndrome.
Family members (Fig. 1A): the mother (II-2), father
(II-1) and brother (III-1), underwent clinical evaluation
and echocardiographic screening. The mother was di-
agnosed with sensorineural deafness and mild cardiac
hypertrophy (left ventricular thickness 1.2 cm). The
brother showed normal echocardiographic data and no
signs of hearing loss. Both mother and maternal grand-
mother were affected by sensorineural hearing loss and
two maternal uncles and one aunt (not available for
evaluation) were described as being affected by cystic
renal disease. The father had normal echocardiograph-
ic findings. The family environment appeared to be
quite critical, with conflicts among members that pre-
vented the extension of the clinical and molecular eval-
uation to all living relatives, in particular to the mater-
nal uncles.
At 12 and 18 months of follow-up the patient was
clinically stable with a creatinine value of about 2.8
mg/dl and no dyspnea. The possibility of a double
transplantation of the kidney and heart was excluded
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because of the very high risk associated with such
surgery and in view of the patient’s clinical conditions,
mental disorder and the critical family environment.
Molecular data. mtDNA of the proband was fully se-
quenced and showed a novel G1644A transition affect-
ing the tRNAVal (Fig. 1 B, C and D), besides A2706G,
T14766C, T16086C non-pathological mutations. The
G1644A transition was present in the DNA of the
proband’s mother and brother. The mutant mtDNA was
quantified as 85.4, 76 and 74.1% in the total DNA from
the peripheral blood DNA of the proband, mother and
unaffected brother, respectively. Heteroplasmy, evalu-
ated using densitometric analysis, is shown for subjects
II-2, III-1 and III-2 in figure 1C (lanes 2, 3 and 4): two
bands of 148 and 124 bp are shown indicating the pres-
ence of mutated and normal mtDNA molecules.
Discussion
The present family highlights the complex clinical
problems that may be associated with mtDNA defects:
1) the phenotype heterogeneity: different organs and
tissues may be affected in the same patients or mem-
bers of the same family. Cardiomyopathy may occur in
patients with MELAS6-10,15, but it may also represent
the only clinically relevant phenotype in patients with
462
Ital Heart J Vol 5 June 2004
Figure 1. A: family tree. Full black = affected proband; upper left black quarter = deafness; upper right black quarter = cystic kidney disease; lower
right black quarter = mild left ventricular hypertrophy in the mother of the proband. Upper –: family members who were submitted to genetic testing.
B: sequence analysis from the polymerase chain reaction product of the region with the G1644A mutation. C: MboI analysis (148, 124, 24 bp). Lane 1:
molecular weight markers; lane 2: proband (III-2); lane 3: mother (II-2); lane 4: brother (III-1); lane 5: father (II-1); lane 6: wild type (wt) control;
lane 7: uncut wt. D: secondary structure of the mitochondrial tRNAVal. The G1644A new mutation is indicated in the red circle. The black circle indi-
cates the other tRNAVal mutation identified in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode (MELAS)
syndrome4. HCM = hypertrophic cardiomyopathy; MWM = molecular weight markers; nd = not determined.
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Table I. Alignment of the mitochondrial transfer RNAVal region including the G1644A position in 79 different species.
Anticodon 1644
↓ ↓
Man (reference sequence) TTACACTTAGGA G ATTTCAACTTAA
Bacteria
Methanococcus vani. (archae) TTACAAGGCGAG G GTCGCCGGTTCG
Mycoplasma capricolum TTACAAGCAGGC G GTCATAGGTTCA
Mycoplasma mycoides TTACAAGCAGGC G GTCATAGGTTCA
Mycoplasma pneumoniae TTACAAGCATAG G GTCGGGGGTTCG
Acholeplasma laidlawii TTACAAGCAGGG G GTCGGCGGTTCA
Staphylococcus aureus TTACAAGCAGAG G GTCGGCGGTTCG
Lactobacillus bulgaricus TTACAAGCAGAG G GTCACAGGTTCG
Bacillus subtilis TTACAAGCAGAG G GTCGGCGGTTCG
Bacillus sp. PS3 TTACAAGCAAGG G GTCGGCGGTTCG
Escherichia coli TTACAAGGAGGG G GTCGGCGGTTCG
Azospirillum lipo. TTACAAGCAGAG G GTCGGCGGTTCG
Unicellular eukaryotes
Prototheca wickerhamii TTACAACGAGAT G GTTAATGGTTCG
Aspergillus nidulans TTACACACGAAG G TCAGGTGTTCAA
Podospora anserina TTACACACGGAA G GCTATGAGTTCG
Saccharomyces cerevisiae TTACACACGAAA G ATTATAGGTTCG
Candida parapsilopsis TTACACGTCTTA G  TTAATGGTTCGA
Torulopsis glabrata TTACACACGAAA G ATTATAGGTTCG
Trichophyton mentagrophytes TTACACACGAAG G TGCAGGTGTTCA
Animals
Gorilla gorilla TTACACTTAGGA G ATTTCAACTTAA
Pan paniscus TTACACTTAGGA G ATTTCAACTTAA
Pan troglodytes TTACACTTAGGA G ATTTCAACTTAA
Pongo pygmaeus Abelii TTACACTTAGGA G ATTTCAATTCAA
Hylobates lar TTACACCCGGGA G ATTTCAATTAAC
Pongo pygmaeus TTACACTTAGGA G ATTTCAACTTAA
Ursus americanus TTACACCCAGAA G ATTTCACGTTAT
Talpa europea TTACACCCAGAA G ATTTCATTAAAA
Ovis aries TTACACCTAGAA G ATTTCACACATT
Hippopotamus amphibius TTACACCCAGAA G ATTTCACAATAA
Gallus gallus TTACACCTCAAA G ATACCCTCAACA
Felis catus TTACACCCAGAA G ATTTCATATTAA
Diplophos taenia TTACACCGAAGA G ACGCCCGTGCAA
Canis familiaris CTACACCCAGAA G ATTTCATTACTT
Coturnix chinensis TTACACCTGAAA G ATGCCCTTTAAA
Falco peregrinus TTACACCTGAAA G ATGTCTGTCACC
Ciconia ciconia TTACACCTGAAA G ATGTCTGCTACC
Cavia porcellus TTACACCCGGAA G ATTTCAGCCACC
Anguilla japonica TTACACCGAGAA G ACACTCGTGCAA
Equus asinus TTACACCTAGAA G ATTTCACTCAGA
Equus caballus TTACACCTAGAA G ATTTCACTCAAA
Antigonia capros TTACACTGAGGA G TCATCCGTGCAA
Rhinoceros unicornis TTACACCCAGGA G ATTTCATACAAA
Sus scrofa TTACACCTAGAA G ATCCCACAATGT
Struthio camelus TTACACCTGAGA G ATGTCTAACATA
Orycteropus afer CTACACCCAGAA G ATTTCAATAACC
Salmo salar TTACACCGAGAA G ACATCCGTGCAA
Zeus faber TTACACCGAGAA G CCGCCCGTGCAA
Ceratotherium simum TTACACCCAGGA G ATTTCATACAAA
Euthynnus alletteratus TTACACTGAAAA G TCATCCGTGCAA
Paralichtys olivaceus TTACACCGAGGA G ACATCACGTGCA
Squalus acanthias TTACACCTGAAA G ATGTCTACATAA
Ascaris suum TTACAATGAGAG G GTTTATTAAGTT
Caenorhabditis elegans TTACAATGAGAG G GTTTATTAAGTT
Aedes albopictus TTACATTGAAAA G AAATTTGTGCAA
Apis mellifera TTACAGTGAAAA G ATTAAAAAATTA
Drosophila yakuba TTACATTGAAAA G ATTTTTGTGCAA
Pisaster ochraceus TTACACAGAGAA G AAGTTTGTGAAA
Asterina pectinifera TTACACAGAGCT G ATATTTGTGCAA
Asterias forbesii TTACACGGAGAA G AAGTTTGTGAAA
Cyprinus carpio TTACACCGAGAA G ACATCCATGCAA
(continues)
mtDNA mutations28. In our family, the mild hypertro-
phy of the proband’s mother cannot be defined as HCM
because of the borderline values of the ventricular
thickness, the absence of diastolic filling abnormalities
and the normal atrial size and function. Both mother
and grandmother of the proband however are affected
by hearing loss that constitutes one of the typical phe-
notypes associated with mtDNA pathological defects,
while the proband’s brother does not show any clinical
phenotype, neither cardiac nor auditory. It is worth not-
ing that the phenotype variability is typical of mtDNA-
related diseases. However, the absence of tissue biop-
sies prevents any measurement of the amount of mutant
DNA in different tissues and we did not expect any use-
ful clinical information from endomyocardial biopsy
that was hence not performed. The molecular genetic
data in this family are those obtained from blood DNA
where the amount of mutant molecules was higher in
the proband than in the mother and unaffected brother
(85.4, 76.0 and 74.1%, respectively). The phenotypic
expression of heteroplasmic mutations is linked to the
amount of mutant mtDNA, with threshold values vari-
able in different tissues, depending on their specific en-
ergy demands. This behavior is well known and typical
of mtDNA mutations29-31;
2) the cardiac involvement: the typical HCM associat-
ed with mtDNA defects is symmetrical and frequently
evolves through dilation and congestive heart failure.
Our patient displayed both symmetrical hypertrophy
and left ventricular dysfunction. Asymmetrical hyper-
trophy usually recurs in HCM caused by nuclear gene
defects;
3) the ethical issue of cardiac transplantation in a pa-
tient with a complex and severe syndrome, associated
with mental retardation: this aspect is beyond the scope
of the present study. However, although all patients
have equal rights to be given the best treatment, this
particular syndrome is unlikely to enter the field of
transplantation for obvious reasons. No organ trans-
plant has ever been performed in patients with such a
syndrome.
The G1644A mutation found in our family has all
the necessary requirements to be defined as pathologi-
cal:
• the G at the 1644 position is a very conserved base as
shown by the sequence alignment reported in table I; the
G at 1644 is also maintained in those mt-tRNAVal where
the base sequence of the region is highly variable;
• the G → A mutation at 1644 np of the tRNAVal is lo-
cated in the unique tRNAVal, two bases 5’ apart from the
G1642A transition (Fig. 1D), described as being etio-
logic for a MELAS syndrome4;
• the mutation, as indicated both by sequencing (Fig.
1B), agarose gel electrophoresis of the mismatch am-
plified mtDNA fragment (Fig. 1C) digested with MboI
and densitometric analysis, is heteroplasmic;
• the mutation has not been found in our series of
healthy control subjects.
In conclusion, the novel mtDNA tRNAVal mutation
identified in our family is associated with HCM and
MELAS as well as with other minor phenotypes typical
of mtDNA defects (i.e. deafness). Although only a few
patients with MELAS may necessitate cardiological
evaluation for a coexisting HCM (2 cases described to
date6-10,15), we recommend that cardiologists be aware
of this association as well as of the non-cardiac signs
that may address the diagnosis to a mtDNA defect-re-
lated disease.
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Anopheles quadrimaculatus TTACATTGAAAA G AAATTTGTGCAA
Crossostoma lacustre TTACACCGAGAA G ACATCCATGCGA
Chicken TTACACCTGAAA G ATACCCTCAACA
Rat CTACACCCAGAA G AATTCATAAAAA
Mouse CTACACCCAGAA G ATTTCATGACCA
Balaenoptera physalus TTACACCTAGAA G ATTCCACAGCCC
Balaenoptera musc. TTACACCTAGAA G ATTCCACAGCCC
Bovine TTACACCTAGAA G ACTTCATTCATT
Halichoerus grypus TTACACCCAGAA G ATTTCACACCCA
Phoca vitulina TTACACCCAGAA G ATTTCACACCCA
Aepyceros melampus TTACACCTAGAA G ATTTCATACACA
Boselaphus tragoc. TTACACCTAGAA G ATTTCACATACG
Cephalophus maxw. TTACACCTAGAA G ATTTCACCCACC
Damaliscus dorcas TTACACCTAGAA G ATTTCACACATC
Gazella thomsoni TTACACCTAGAA G ATTCCATACACT
Kobus ellipsiprym. TTACACCTAGAA G ATTTCACACGCC
Madoqua kirki TTACACCTAGAA G ATTTCACACACT
Oryx gazella TTACACCTAGAA G ATTCACATATCA
Tragelaphus imber. TTACACCTAGAA G ATTTCACACACC
Patient (III-2) TTACACTTAGGA A ATTTCAACTTAA
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